Ascidian, Lilly sign RNA exon editing pact for inherited kidney diseases worth up to $1.9 billion

  • Apple Tree Partners portfolio company Ascidian Therapeutics signed a global research collaboration, licensing deal with Lilly on RNA exon editors for monogenic kidney diseases.
  • Lilly secured exclusive, target-specific rights for undisclosed kidney disease targets; Ascidian leads discovery, selected preclinical work.
  • Lilly will run additional preclinical work, clinical development, manufacturing, commercialization.
  • Ascidian is eligible for up to USD 1.9 billion in upfront, milestones, tiered royalties.
  • Deal includes an option for Lilly to expand the collaboration to additional targets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apple Tree Partners published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.